Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Prostate Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
31 drugs · 100 active trials
7 drugs · 60 active trials
24 drugs · 405 active trials
Outside the funnel: Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 2 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Pacritinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Jun 1, 2021 |
| Pegargiminase | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Sep 6, 2011 |
| Sapanisertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2014-03 |
| Tivozanib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Sep 3, 2013 |
| Belzutifan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 17, 2016 |
| Berzosertib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | May 29, 2019 |
| Binimetinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Camizestrant | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Durvalumab/Tremelimumab Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 1, 2018 |
| Enfortumab Vedotin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 5, 2022 |
| Fexagratinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Immunotherapy | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jan 1, 2024 |
| Inavolisib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 11, 2026 |
| Ipilimumab/Nivolumab Regimen | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 6, 2018 |
| Larotrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Lutetium (177lu) Oxodotreotide | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Dec 27, 2023 |
| Omacetaxine Mepesuccinate | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 20, 2025 |
| Rezatapopt | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 29, 2020 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 24, 2018 |
| Savolitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 1, 2018 |
| Tarlatamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 31, 2025 |
| Taselisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2015 |
| Trastuzumab Deruxtecan | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 12, 2020 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | 2000-09 |
| Filgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | 1997-03 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 8 | 0 | — | — | Sep 1, 2004 |
| Gefitinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | Apr 24, 2001 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 1997-10 |
| Chemotherapy | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 1995-08 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2001-10 |
| Pazopanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2006-06 |
| Cixutumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2007-08 |
| Lapatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2004-11 |
| Panitumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2000-04 |
| Panobinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2008-02 |
| Pemetrexed | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2005-02 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2005-12 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2011-08 |
| Tremelimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Dec 15, 2016 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1997-08 |
| Azacitidine | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2000-05 |
| Enzastaurin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-01 |
| Erlotinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-08 |
| Nab-paclitaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2019-11 |
| Oxaliplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-11 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Aug 10, 2004 |
| Tanespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1999-07 |
| Tisotumab Vedotin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 30, 2013 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Apr 20, 2009 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.